Sanofi said it will pursue regulatory submissions for amlitelimab in atopic dermatitis despite mixed results across its Phase 3 program. The company cited the totality of the data and signaled intent to file globally, positioning amlitelimab as a potential successor to its Dupixent franchise. One Phase 3 trial met primary endpoints while another narrowly missed a statistical threshold under certain regional analyses; an additional safety study flagged one case of skin cancer. Sanofi’s decision to advance filings highlights differing regulatory standards across regions and the company’s strategy to leverage positive cohorts and convenience claims in its approval strategy.